Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
1 other identifier
observational
25
1 country
7
Brief Summary
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2023
Typical duration for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 19, 2023
CompletedFirst Submitted
Initial submission to the registry
July 26, 2023
CompletedFirst Posted
Study publicly available on registry
August 3, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 5, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
February 23, 2026
February 1, 2026
3.3 years
July 26, 2023
February 19, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Create Data Set
The goal of this registry is to create a data set from real world clinical and patient reported data collected using an electronic care planning system (CPS) that is used in routine care for cancer patients on active treatment
1 year
Interventions
online weekly survey
Eligibility Criteria
patients receiving cancer treatment for breast, lung, GI or multiple myeloma
You may qualify if:
- All participants must be 18 years of age or older.
- Subjects may be any stage and anywhere in the treatment continuum.
- Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma.
- Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.
- All participants must be able to understand English.
You may not qualify if:
- Any patient who cannot understand written or spoken English.
- Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer.
- Any patient on a treatment clinical trial.
- Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Yale Cancer Center
New Haven, Connecticut, 06511, United States
Northshore University Health System
Evanston, Illinois, 31024, United States
Univeristy of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Duke
Durham, North Carolina, 27707, United States
Cleveland Clinic Mercy Hospital
Canton, Ohio, 44708, United States
University Hospitals Seidman Cancer Center
Cleveland, Ohio, 44106, United States
Tri-County Hematology & Oncology Associates, Inc.
Massillon, Ohio, 44646, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 26, 2023
First Posted
August 3, 2023
Study Start
July 19, 2023
Primary Completion (Estimated)
November 5, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
February 23, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share